

**Table 1.** Characteristics of patients and alloH SCT procedure according to the type of GVHD prophylaxis.

| GVHD prophylaxis<br>N=1,544                 | CNI-MTX<br>N=203 (13.1%) | CNI-Sirolimus<br>N=117 (7.6%) | ATG-based<br>N=118 (7.6%) | PCTy-based<br>N=1,013 (65.6%) | Other<br>N=93 (6%) | P-<br>value |
|---|--------------------------|-------------------------------|---------------------------|-------------------------------|--------------------|-------------|
| Age at transplant, median (IQR)             | 50.2 (39.6; 57.2)        | 61.7 (56.4; 66.5)             | 52.5 (42.8; 60.2)         | 53.6 (41.8; 62.2)             | 57.1 (43.6; 62)    | <0.001      |
| Receptor gender, n (%)                      |                          |                               |                           |                               |                    | 0.919       |
| Female                                      | 93 (45.8)                | 49 (42.2)                     | 51 (43.2)                 | 440 (43.6)                    | 44 (47.3)          |             |
| Male  | 110 (54.2)               | 67 (57.8)                     | 67 (56.8)                 | 570 (56.4)                    | 49 (52.7)          |             |
| Diagnostic, n (%)                           |                          |                               |                           |                               |                    | <0.001      |
| Acute myeloid leukemia                      | 83 (40.9)                | 48 (41.0)                     | 31 (26.3)                 | 370 (36.5)                    | 20 (21.5)          |             |
| Myelodysplastic syndrome                    | 26 (12.8)                | 33 (28.2)                     | 17 (14.4)                 | 138 (13.6)                    | 18 (19.4)          |             |
| Acute lymphoblastic leukemia                | 30 (14.8)                | 5 (4.3)                       | 28 (23.7)                 | 113 (11.2)                    | 8 (8.6)            |             |
| Non-Hodgkin lymphoma                        | 24 (11.8)                | 11 (9.4)                      | 12 (10.2)                 | 141 (13.9)                    | 15 (16.1)          |             |
| Other                                       | 40 (19.7)                | 20 (17.1)                     | 23 (15.1)                 | 251 (24.8)                    | 32 (34.4)          |             |
| Disease Risk Index, n (%)                   |                          |                               |                           |                               |                    | <0.001      |
| Low-Intermediate                            | 71 (35.0)                | 36 (30.8)                     | 64 (54.2)                 | 544 (53.7)                    | 41 (44.1)          |             |
| High-Very high                              | 59 (29.1)                | 34 (29.1)                     | 32 (27.1)                 | 295 (29.1)                    | 17 (18.3)          |             |
| Missing/Not classifiable                    | 73 (36.0)                | 47 (40.2)                     | 22 (18.6)                 | 174 (17.2)                    | 35 (37.6)          |             |
| Disease status at transplant, n (%)         |                          |                               |                           |                               |                    | 0.267       |
| Complete remission                          | 140 (69.0)               | 77 (65.8)                     | 70 (59.3)                 | 659 (65.1)                    | 52 (55.9)          |             |
| Partial remission                           | 26 (12.8)                | 8 (6.8)                       | 18 (15.3)                 | 134 (13.2)                    | 16 (17.2)          |             |
| Stable disease                              | 19 (9.4)                 | 18 (15.4)                     | 18 (15.3)                 | 125 (12.3)                    | 12 (12.9)          |             |
| Progressive disease                         | 12 (5.9)                 | 10 (8.5)                      | 10 (8.5)                  | 81 (8.0)                      | 12 (12.9)          |             |
| Not assessed                                | 6 (3.0)                  | 4 (3.4)                       | 2 (1.7)                   | 14 (1.4)                      | 1 (1.1)            |             |
| Karnofsky score <80, n (%)                  | 5 (2.5)                  | 6 (5.1)                       | 9 (7.6)                   | 39 (3.8)                      | 7 (7.5)            | 0.031       |
| HCT-CI $\geq 3$ , n (%)                     | 59 (29.1)                | 28 (23.9)                     | 41 (34.7)                 | 422 (41.7)                    | 31 (33.3)          | <0.001      |
| Type of donor, n (%)                        |                          |                               |                           |                               |                    | <0.001      |
| MRD   | 148 (72.9)               | 70 (59.8)                     | 17 (14.4)                 | 221 (21.8)                    | 52 (55.9)          |             |
| MUD   | 50 (24.6)                | 42 (35.9)                     | 70 (59.3)                 | 268 (26.5)                    | 27 (29.0)          |             |
| MMUD/MMRD                                   | 4 (2.0)                  | 5 (4.3)                       | 30 (25.4)                 | 110 (10.9)                    | 3 (3.2)            |             |
| Haploidentical                              | 1 (0.5)                  | 0 (0.0)                       | 1 (0.8)                   | 414 (40.9)                    | 11 (11.8)          |             |
| Female donor-male receptor, n (%)           | 41 (20.3)                | 25 (21.9)                     | 15 (12.7)                 | 185 (18.6)                    | 19 (20.4)          | 0.395       |
| Peripheral Blood as Stem cell source, n (%) | 179 (88.6)               | 115 (99.1)                    | 104 (88.1)                | 894 (88.6)                    | 79 (84.8)          | <0.001      |
| Conditioning regimen, n (%)                 |                          |                               |                           |                               |                    | <0.001      |
| Myeloablative                               | 118 (58.4)               | 3 (2.6)                       | 64 (54.2)                 | 415 (41.3)                    | 31 (33.7)          |             |
| Reduced intensity/Non-myeloablative         | 84 (41.6)                | 112 (97.4)                    | 54 (45.8)                 | 591 (58.7)                    | 61 (66.3)          |             |

CNI, calcineurin inhibitors; MTX, methotrexate; ATG, antithymocyte globulin; PCTy, post-transplant cyclophosphamide; HCT-CI, Hematopoietic Cell Transplant Comorbidity Index; CML, chronic myeloid leukemia; MRD, matched related donor; MUD, matched unrelated donor; MMUD, mismatched unrelated donor; MMRD, mismatched related donor; CMV, cytomegalovirus.